Pomalidomide, an investigational third-generation immunomodulatory drug, was more effective when combined with low-dose dexamethasone than high-dose in a clinical trial presented at the annual meeting of the American Society of Hematology.
Patrice Wendling interviewed Dr. Meletios A. Dimopoulos on why reducing toxicity is important in multiple myeloma regimens.